Ansari, S., Kamdar, M., Papp, E., Shadman, M., Abramson, J., Topçuoglu, B. D., Yang, P., Stepan, L., Ray, P., Przespolewski, A., Juluri, K. R., Bleickardt, E., Roy, D., Crotta, A., Campbell, T. B., Rytlewski, J. A., Okal, A., Thompson, E., Peiser, L. (2025). INSIGHT: A baseline laboratory profile independently predicts outcomes and demonstrates superiority of lisocabtagene maraleucel (liso-cel) over standard of care (SOC) in second-line (2L) large B-cell lymphoma (LBCL) regardless of baseline profile. Blood. https://doi.org/10.1182/blood-2025-1775